10-Q: Plus Therapeutics Boosts Cash, Advances Pipeline Amid Nasdaq Scrutiny

Plus Therapeutics reported a significant increase in cash and working capital, driven by recent financings, while advancing its radiotherapeutic pipeline and diagnostic platform, despite an increased net loss and ongoing Nasdaq bid price compliance challenges.

Summary

• Net loss increased to $16.7 million for the nine months ended September 30, 2025, from $9.1 million in the same period of 2024.
• Cash and cash equivalents significantly increased to $13.3 million as of September 30, 2025, from $76 thousand at December 31, 2024.
• Working capital improved from a deficit of $10.3 million at December 31, 2024, to a positive $4.0 million at September 30, 2025.
• Operating cash burn increased to $14.5 million for the nine months ended September 30, 2025, compared to $9.3 million in the prior year.
• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on March 7, 2025, but remains under a one-year monitoring period until August 22, 2026.
• Received a Nasdaq notice on May 16, 2025, for non-compliance with the $1.00 minimum bid price requirement, with a compliance deadline of November 12, 2025.
• Stockholders approved discretionary authority for a reverse stock split (1-for-2 to 1-for-250) to address bid price deficiency.
• Phase 1 of the ReSPECT-LM clinical trial for leptomeningeal metastases completed on February 26, 2025, with interim results showing decreased CSF tumor cell count and good tolerability.
• FDA cleared the Investigational New Drug (IND) application for REYOBIQ for pediatric brain cancer (HGG and ependymoma) on June 25, 2025, with enrollment anticipated before the end of 2025.
• CNSide Diagnostics, a wholly-owned subsidiary, received CLIA accreditation for its Houston lab and signed a national agreement with UnitedHealthcare, effective September 15, 2025, covering over 51 million people.
• Plans to re-introduce the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test (CNSide Test) to the U.S. market starting Q4 2025.
• Secured substantial capital through the Lincoln Park Purchase Agreement ($19.6 million) and March 2025 Private Placement ($15.0 million).

Sentiment

Score: 6

Explanation: While the net loss and operating cash burn increased, the company significantly improved its liquidity position through substantial capital raises. Clinical programs are advancing with key regulatory clearances and trial completions, and the diagnostic platform secured a major commercial agreement. However, ongoing Nasdaq bid price compliance issues and the continued need for external financing temper the overall sentiment.

Positives

• Cash and cash equivalents increased substantially to $13.289 million from $76 thousand at December 31, 2024.
• Working capital improved significantly from a deficit of $10.292 million at December 31, 2024, to a positive $3.970 million at September 30, 2025.
• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on March 7, 2025.
• Completed Phase 1 of the ReSPECT-LM clinical trial, showing positive interim results including decreased CSF tumor cell count and good tolerability.
• FDA cleared the IND for REYOBIQ in pediatric brain cancer, allowing the Phase 1/2a trial to proceed with enrollment anticipated before the end of 2025.
• CNSide Diagnostics received CLIA accreditation and secured a national commercial agreement with UnitedHealthcare, effective September 15, 2025, covering over 51 million people, paving the way for commercial launch.
• Secured substantial capital through the Lincoln Park Purchase Agreement ($19.6 million) and March 2025 Private Placement ($15.0 million).
• Operating loss decreased to $(9.556) million for the nine months ended September 30, 2025, from $(10.795) million in the prior year.

Negatives

• Net loss increased significantly to $(16.673) million for the nine months ended September 30, 2025, from $(9.075) million in the same period of 2024.
• Net cash used in operating activities increased to $(14.518) million, indicating a higher cash burn from core operations.
• Accumulated deficit grew to $(510.152) million as of September 30, 2025.
• Ongoing non-compliance with Nasdaq's $1.00 minimum bid price requirement, with a compliance deadline of November 12, 2025.
• Subject to a one-year Nasdaq panel monitoring period for the Equity Standard until August 22, 2026, with stricter delisting rules if non-compliance recurs.
• Grant revenue decreased to $3.846 million for the nine months ended September 30, 2025, from $4.412 million in the prior year.
• General and administrative expenses increased by $1.2 million for the nine months ended September 30, 2025.

Risks

• Inability to regain compliance with Nasdaq's Minimum Bid Requirement, potentially leading to delisting of common stock.
• Failure to maintain compliance with Nasdaq's Equity Standard during the one-year monitoring period, which could lead to delisting without a cure period.
• Ongoing need to raise additional capital to fund clinical development programs, commercialization of the CNSide Test, and other operations, with no assurance of future capital availability.
• Early stage of product candidates and therapies, with inherent uncertainties relating to the clinical trials of product candidates and therapies.
• Risks associated with laws or regulatory requirements applicable to the company.
• Market conditions, product performance, potential litigation, and competition within the radiotherapeutics and oncological medicine fields.
• Potential for CPRIT to require repayment of grant proceeds if the contract is terminated early due to default by the company or relocation outside of Texas.

Future Outlook

Management expects aggregate research and development expenses to increase during the remainder of 2025 as the ReSPECT-LM dose optimization trial commences and preparations for the CNSide Test launch intensify. General and administrative expenditures are also projected to rise due to the commercial launch of the CNSide Test, requiring increased administrative and sales headcount. The company continues to seek additional capital to fund future clinical development, commercialization, and operations.

Management Comments

• We are planning for the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test (the CNSide Test), which is a laboratory developed test (LDT), to be re-introduced to the U.S. market starting in the fourth quarter of 2025.
• We anticipate beginning enrollment for our Phase 1 ReSPECT-PBC clinical trial in 2025.
• We anticipate to begin enrollment in our ReSPECT-PBC clinical trial before the end of 2025.
• We expect aggregate research and development expenses to increase during the remainder of 2025 as compared to the corresponding comparable period in 2024 as we commence the ReSPECT-LM dose optimization trial for REYOBIQ and prepare for the launch of the CNSide Test.
• We expect general and administrative expenditures to increase during the remainder of 2025 as compared to the corresponding comparable period in 2024 as we work towards the commercial launch of the CNSide Test, which will require an increase in administrative and sales headcount.

Industry Context

The company operates in the highly specialized and competitive fields of radiotherapeutics for central nervous system (CNS) cancers and cancer diagnostics. Its focus on targeted radiation delivery aims to overcome limitations of traditional therapies like external beam radiation, which often damage healthy tissue and have limited efficacy in aggressive cancers like glioblastoma (GBM) and leptomeningeal metastases (LM). The development of the CNSide Test aligns with the growing trend towards precision medicine and personalized diagnostics in oncology, enabling better treatment selection and monitoring. The national agreement with UnitedHealthcare for the CNSide Test is a significant step towards broader market acceptance and reimbursement, a critical factor in the diagnostic industry. The company's pipeline, including REYOBIQ and 188RNL-BAM, positions it within the innovative segment of oncology, seeking to address unmet medical needs in difficult-to-treat cancers.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• From time to time, the company is subject to legal proceedings and claims, whether asserted or unasserted, that arise in the ordinary course of business. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.

Related Party Transactions

• The May 2024 Private Placement included participation from certain of the company's directors and executive officers (Company Insiders).

Stakeholder Impact

• Shareholders face potential for significant dilution from ongoing capital raises and the risk of delisting from Nasdaq, which could harm liquidity and market price. A potential reverse stock split, while necessary for compliance, may be perceived negatively. Positive clinical trial progress and commercialization efforts could increase long-term value.
• Employees may see increased opportunities with expansion plans for the CNSide Test, potentially leading to increased administrative and sales headcount. Stock-based compensation increased, indicating continued incentives.
• Future customers (patients and healthcare providers) could benefit from new diagnostic and therapeutic options for cancer, such as the CNSide Test and REYOBIQ, if successfully commercialized.
• Creditors benefit from the repayment of the Pershing Credit Facility and other notes payable, reducing immediate debt obligations, but the ongoing need for capital raises questions about long-term solvency without further funding.

Next Steps

• Target full enrollment into Phase 2 of the ReSPECT-GBM Trial by the end of 2026.
• Complete trial closeout procedures, final data review, monitoring, and prepare a clinical study report and manuscript for the ReSPECT-LM Phase 1 trial.
• Continue enrolling patients in the ReSPECT LM Multi-dose Phase 1/2 Study.
• Anticipate beginning enrollment for the Phase 1 ReSPECT-PBC clinical trial before the end of 2025.
• Develop the Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) technology and complete early preclinical studies to support a future FDA IND submission.
• Re-introduce the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test (CNSide Test) to the U.S. market starting in Q4 2025, beginning in Texas, followed by expansion into additional states in 2026.
• Roll out additional expanded CNS testing capabilities over the next year.
• Monitor the closing bid price of common stock and consider options, including a reverse stock split, to regain Nasdaq Minimum Bid Requirement compliance by November 12, 2025.
• Continue to seek additional capital from other financing alternatives.
• Commence the Houston Lease on or about November 1, 2026.

Key Dates

Recommendation

While Plus Therapeutics demonstrated strong progress in securing capital, significantly improving its cash position and working capital, and advancing its clinical pipeline with key regulatory clearances and trial completions, the company continues to operate at a substantial net loss and increased cash burn from operations. The ongoing Nasdaq bid price non-compliance and the strict monitoring period for equity standards present material risks to its listing status and investor confidence. The potential for a reverse stock split, while necessary for compliance, often carries negative sentiment. For a seasoned investor, the positive developments in financing and clinical progress are balanced by the persistent operational losses and listing uncertainties, warranting a 'hold' position to observe further execution on clinical milestones and sustained financial stability.

Keywords

Plus Therapeutics, PSTV, SEC filing, 10-Q, Q3 2025, financial results, radiotherapeutics, CNS cancers, REYOBIQ, glioblastoma, leptomeningeal metastases, pediatric brain cancer, CNSide Test, diagnostics, Nasdaq compliance, capital raise, clinical trials, oncology, biotechnology, pharmaceutical